Edward Hsiao, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, HSE, #901G
San Francisco CA 94143
Phone415-476-9732
ORCID ORCID Icon0000-0001-8924-106X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Johns Hopkins UniversityM.D.2001School of Medicine
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    EDUCATION/CLINICAL TRAINING
    MD: MD, PhD, Johns Hopkins Medical School, 2001
    Residency: Johns Hopkins Hospital, Baltimore, MD, Internal Medicine, 2001-2004
    Fellowship: UCSF, Division of Diabetes, Endocrinology and Metabolism, 2004-2007
    Board Certifications: Internal Medicine, 2004; Endocrinology and Metabolism, 2006

    ACADEMIC INTERESTS
    My research is driven by a desire to understand how major hormonal and regulatory pathways determine the specification, differentiation, and morphogenesis of mesenchymal tissues such as bone, cartilage, muscle, and fat. Mis-regulation of these pathways leads to significant medical diseases, including the inappropriate formation of mineralized tissues in atherosclerosis, heterotopic ossification, and cancer.

    My research focuses on understanding how these regulatory signals control normal and pathologic tissue formation as a way to identifying new therapeutic avenues for treating human diseases. Our laboratory takes a comprehensive approach to understanding hormone signaling in human diseases using synthetic biology approaches, mouse models, and human stem cell models.

    By combining multiple approaches with state-of-the art methods, our laboratory is working to develop a broader understanding of the biology underlying skeletal development, devise novel therapeutic approaches for treating human skeletal disorders and bone injuries, and examine how hormone signals affect important tissues such as fat, muscle, bone, cartilage, and blood vessels.

    CLINICAL INTERESTS:
    General Endocrinology with an interest in inherited skeletal diseases, including fibrous dysplasia of the bone (FD), McCune-Albright syndrome (MAS), and fibrodysplasia ossificans progressiva (FOP).

    Appointments: 415-353-2350
    Availability: General Endocrinology, 3rd Tuesday PM of each month

    Laboratory website: https://hsiaolab.ucsf.edu

    Collapse Research 
    Collapse Research Activities and Funding
    Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus
    NIH UH3DK120004Sep 20, 2018 - Jul 31, 2023
    Role: Co-Principal Investigator
    Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus
    NIH UG3DK120004Sep 20, 2018 - Jul 31, 2020
    Role: Co-Principal Investigator
    Pharmacologic modulation of innate immune dysfunction in heterotopic ossification
    NIH R01AR073015Sep 1, 2018 - Jun 30, 2022
    Role: Principal Investigator
    Elucidating skeletal stem cell function using engineered 3D multicellular structures
    NIH R21AR072778Mar 13, 2018 - Jan 31, 2020
    Role: Principal Investigator
    Innate immune regulation of stem cells in bone formation
    NIH R01AR066735Sep 1, 2015 - Aug 31, 2021
    Role: Principal Investigator
    A New Regulator of Trabecular Bone Formation
    NIH R03AR060986Apr 1, 2011 - Jan 31, 2015
    Role: Principal Investigator
    Regulation of Bone Formation by G-protein Signaling
    NIH K08AR056299Jul 3, 2009 - Jun 30, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Collaboration Interests

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nat Med. 2024 Jun 21. Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula I, Howle J, Ch'ng S, Gonzalez M, Saw RPM, Pennington TE, Lo SN, Scolyer RA, Menzies AM. PMID: 38907159.
      View in: PubMed   Mentions:    Fields:    
    2. Long term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva. Rheumatology (Oxford). 2024 May 11. Haviv R, Zeitlin L, Moshe V, Ziv A, Rabinowicz N, De Benedetti F, Prencipe G, Matteo V, De Cunto CL, Hsiao EC, Uziel Y. PMID: 38733591.
      View in: PubMed   Mentions:    Fields:    
    3. Pulmonary BRAF-driven Langerhans cell histiocytosis following selpercatinib use in metastatic medullary thyroid cancer. Endocrinol Diabetes Metab Case Rep. 2024 Apr 01; 2024(2). Wu K, Kumar S, Hsiao E, Kerridge I, Qiu MR, Siddall R, Clifton-Bligh R, Gill AJ, Gild ML. PMID: 38804700.
      View in: PubMed   Mentions:
    4. Immunologic Aspects in Fibrodysplasia Ossificans Progressiva. Biomolecules. 2024 Mar 16; 14(3). Diolintzi A, Pervin MS, Hsiao EC. PMID: 38540775; PMCID: PMC10967946.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification. Biomolecules. 2024 Mar 14; 14(3). Juan C, Bancroft AC, Choi JH, Nunez JH, Pagani CA, Lin YS, Hsiao EC, Levi B. PMID: 38540768; PMCID: PMC10968060.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. MMP-9 deficiency confers resilience in Fibrodysplasia Ossificans Progressiva in a man and mice. J Bone Miner Res. 2024 Feb 16. Lounev V, Groppe JC, Brewer N, Wentworth KL, Smith V, Xu M, Schomburg L, Bhargava P, Al Mukaddam M, Hsiao EC, Shore EM, Pignolo RJ, Kaplan FS. PMID: 38477818.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    7. Wnt pathway inhibition with the porcupine inhibitor LGK974 decreases trabecular bone but not fibrosis in a murine model with fibrotic bone. JBMR Plus. 2024 May; 8(5):ziae011. Lung H, Wentworth KL, Moody T, Zamarioli A, Ram A, Ganesh G, Kang M, Ho S, Hsiao EC. PMID: 38577521; PMCID: PMC10994528.
      View in: PubMed   Mentions:
    8. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024 Jan; 25(1):99-107. Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials . PMID: 38043558.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    9. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva. BMC Med Res Methodol. 2023 11 13; 23(1):269. Pignolo RJ, Al Mukaddam M, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, Le Quan Sang KH, Grogan DR, Marino R, Strahs AR, Kaplan FS. PMID: 37957586; PMCID: PMC10642058.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Frontal bone loss following coronal brow lift: A mimicker of head variant linear morphea. JAAD Case Rep. 2023 Nov; 41:4-6. Kazmi M, Zhang WR, Hsiao E, Gross A, Grouse K, Link TM, Tetzlaff M, Theodosopoulos P, Haemel A. PMID: 37842147; PMCID: PMC10568232.
      View in: PubMed   Mentions:
    11. Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages. Nat Commun. 2023 07 03; 14(1):3902. Groeger M, Matsuo K, Heidary Arash E, Pereira A, Le Guillou D, Pino C, Telles-Silva KA, Maher JJ, Hsiao EC, Willenbring H. PMID: 37400454; PMCID: PMC10318012.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    12. EML4::ALK fusions in complex lymphatic malformations. Pediatr Blood Cancer. 2023 Jun 28; e30516. Apsel Winger B, Devine WP, Hsiao EC, Zapala M, Van Ziffle J, Gupta N, Frieden IJ, Shimano KA. PMID: 37377128.
      View in: PubMed   Mentions:    Fields:    
    13. A Case of Hypercalcemia from PTHrP-Producing Fibromyxoid Sarcoma Responsive to Glucocorticoid Therapy. Calcif Tissue Int. 2023 08; 113(2):246-253. Niu I, Hsiao EC, Wustrack R, Wysolmerski JJ, Dann P, Masharani U. PMID: 37358786; PMCID: PMC10372127.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    14. Improving care pathways for people living with rare bone diseases (RBDs): outcomes from the first RBD Summit. Osteoporos Int. 2023 Aug; 34(8):1301-1310. Chandran M, Alves I, Carpenter T, Davis M, Hsiao EC, Petryk A, Semler JO, Sleiman M. PMID: 37294334; PMCID: PMC10382343.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. CO32 Heterotopic Ossification in Palovarotene-Treated and Untreated Individuals with Fibrodysplasia Ossificans Progressiva: Matched and Weighted Analyses. Value in Health. 2023 Jun 1; 26(6):s20. Mukaddam MM, Baujat BG, Cheung CA, De Cunto DC, Hsiao HE, Keen KR, Marden MJ, Signorovitch SJ, Boing BE, Marino MR, Strahs SA, Pignolo PR. .
      View in: Publisher Site   Mentions:
    16. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility. Clin Orthop Relat Res. 2023 12 01; 481(12):2447-2458. Lindborg CM, Al Mukaddam M, Baujat G, Cho TJ, De Cunto CL, Delai PLR, Eekhoff EMW, Haga N, Hsiao EC, Morhart R, de Ruiter R, Scott C, Seemann P, Szczepanek M, Tabarkiewicz J, Pignolo RJ, Kaplan FS. PMID: 37156007; PMCID: PMC10642855.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System. Small. 2023 08; 19(34):e2203725. Qi L, Matsuo K, Pereira A, Lee YT, Zhong F, He Y, Zushin PH, Gröger M, Sharma A, Willenbring H, Hsiao EC, Stahl A. PMID: 37104853; PMCID: PMC10502939.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    18. A follow-up report on the published paper Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2023 03 20; 18(1):61. Wallace H, Lee RH, Hsiao EC. PMID: 36941608; PMCID: PMC10025781.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    19. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP). J Bone Miner Res. 2023 03; 38(3):381-394. Pignolo RJ, Hsiao EC, Al Mukaddam M, Baujat G, Berglund SK, Brown MA, Cheung AM, De Cunto C, Delai P, Haga N, Kannu P, Keen R, Le Quan Sang KH, Mancilla EE, Marino R, Strahs A, Kaplan FS. PMID: 36583535.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    20. The effects of palovarotene in patients with fibrodysplasia ossificans progressiva: a plain language summary. Future Rare Diseases. 2023 Jan 18; 3(1):frd33. Pignolo PR, Hsiao HE, Mukaddam MM, Baujat BG, Berglund BS, Brown BM, Cheung CA, De Cunto DC, Delai DP, Haga HN, Kannu KP, Keen KR, Le Quan Sang LK, Mancilla ME, Marino MR, Strahs SA, Kaplan KF. .
      View in: Publisher Site   Mentions:
    21. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1R206H -Specific Human Cellular and Zebrafish Models. J Bone Miner Res. 2022 11; 37(11):2058-2076. Wentworth KL, Lalonde RL, Groppe JC, Brewer N, Moody T, Hansberry S, Taylor KE, Shore EM, Kaplan FS, Pignolo RJ, Yelick PC, Hsiao EC. PMID: 36153796; PMCID: PMC9950781.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    22. PSAT208 A Case of Hypercalcemia From PTHrP-Producing Fibromyxoid Sarcoma Responsive to Glucocorticoid Therapy. Journal of the Endocrine Society. 2022 Nov 1; 6(Suppl 1):a212-a213. Niu NI, Hsiao HE, Wustrack WR, Wysolmerski WJ, Dann DP, Masharani MU. .
      View in: Publisher Site   Mentions:
    23. Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Nat Commun. 2022 10 19; 13(1):6175. Yang YS, Kim JM, Xie J, Chaugule S, Lin C, Ma H, Hsiao E, Hong J, Chun H, Shore EM, Kaplan FS, Gao G, Shim JH. PMID: 36258013; PMCID: PMC9579182.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    24. The natural history of fibrodysplasia ossificans progressiva: A prospective, global 36-month study. Genet Med. 2022 Dec; 24(12):2422-2433. Pignolo RJ, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, Al Mukaddam M, Le Quan Sang KH, Wilson A, Marino R, Strahs A, Kaplan FS. PMID: 36152026.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Identification of Risk Factors in the Development of Heterotopic Ossification After Primary Total Hip Arthroplasty. J Clin Endocrinol Metab. 2022 08 18; 107(9):e3944-e3952. Singh S, Morshed S, Motamedi D, Kidane J, Paul A, Hsiao EC, Wentworth KL. PMID: 35451005; PMCID: PMC9387692.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial. J Bone Miner Res. 2022 10; 37(10):1891-1902. Pignolo RJ, Baujat G, Hsiao EC, Keen R, Wilson A, Packman J, Strahs AL, Grogan DR, Kaplan FS. PMID: 35854638.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    27. Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles. Hum Gene Ther. 2022 08; 33(15-16):782-788. Eekhoff EMW, de Ruiter RD, Smilde BJ, Schoenmaker T, de Vries TJ, Netelenbos C, Hsiao EC, Scott C, Haga N, Grunwald Z, De Cunto CL, di Rocco M, Delai PLR, Diecidue RJ, Madhuri V, Cho TJ, Morhart R, Friedman CS, Zasloff M, Pals G, Shim JH, Gao G, Kaplan F, Pignolo RJ, Micha D. PMID: 35502479; PMCID: PMC9419966.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. ACVR1-activating mutation causes neuropathic pain and sensory neuron hyperexcitability in humans. Pain. 2023 01 01; 164(1):43-58. Yu X, Ton AN, Niu Z, Morales BM, Chen J, Braz J, Lai MH, Barruet E, Liu H, Cheung K, Ali S, Chan T, Bigay K, Ho J, Nikolli I, Hansberry S, Wentworth K, Kriegstein A, Basbaum A, Hsiao EC. PMID: 35442931; PMCID: PMC9582048.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    29. Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2022 03 04; 17(1):107. Kou S, Kile S, Kambampati SS, Brady EC, Wallace H, De Sousa CM, Cheung K, Dickey L, Wentworth KL, Hsiao EC. PMID: 35246171; PMCID: PMC8894823.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    30. Corrigendum to "ACVR1R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages" [Bone. 153 2021 Dec; 116129. doi:10.1016/j.bone.2021.116129. Epub 2021 Jul 24. PMID: 34311122]. Bone. 2022 May; 158:116325. Matsuo K, Lepinski A, Chavez RD, Barruet E, Pereira A, Moody TA, Ton AN, Sharma A, Hellman J, Tomoda K, Nakamura MC, Hsiao EC. PMID: 35241401.
      View in: PubMed   Mentions:    Fields:    
    31. The Clinical Significance of Small Vessel Vasculitis on Temporal Artery Biopsies. J Neuroophthalmol. 2022 06 01; 42(2):212-217. Quigley J, Sammel AM, Laurent R, Brewer J, Hsiao E, Schembri G, Fraser CL. PMID: 35195542.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. POSC373 Use of Aids, Assistive Devices and Adaptations by Individuals with Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Results from a Global Natural History Study. Value in Health. 2022 Jan 1; 25(1):s245-s246. Mukaddam MM, Baujat BG, Houchard HA, Hsiao HE, Keen KR, Marino MR, Pignolo PR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    33. A single center evaluation of applicant experiences in virtual interviews across eight internal medicine subspecialty fellowship programs. Med Educ Online. 2021 Dec; 26(1):1946237. Huppert LA, Hsu G, Elnachef N, Flint L, Frank JA, Gensler LS, Hsiao EC, Khanna RR, Qasim A, Schwartz BS, Widera E, Zapata C, Babik JM. PMID: 34187346; PMCID: PMC8253192.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    34. Modeling the ACVR1R206H mutation in human skeletal muscle stem cells. Elife. 2021 11 10; 10. Barruet E, Garcia SM, Wu J, Morales BM, Tamaki S, Moody T, Pomerantz JH, Hsiao EC. PMID: 34755602; PMCID: PMC8691832.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    35. Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Front Endocrinol (Lausanne). 2021; 12:732728. de Ruiter RD, Smilde BJ, Pals G, Bravenboer N, Knaus P, Schoenmaker T, Botman E, Sánchez-Duffhues G, Pacifici M, Pignolo RJ, Shore EM, van Egmond M, Van Oosterwyck H, Kaplan FS, Hsiao EC, Yu PB, Bocciardi R, De Cunto CL, Longo Ribeiro Delai P, de Vries TJ, Hilderbrandt S, Jaspers RT, Keen R, Koolwijk P, Morhart R, Netelenbos JC, Rustemeyer T, Scott C, Stockklausner C, Ten Dijke P, Triffit J, Ventura F, Ravazzolo R, Micha D, Eekhoff EMW. PMID: 34858325; PMCID: PMC8631510.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    36. Social and Clinical Impact of COVID-19 on Patients with Fibrodysplasia Ossificans Progressiva. Res Sq. 2021 Sep 16. Kou S, Kile S, Kambampati SS, Brady EC, Wallace H, De Sousa CM, Cheung K, Dickey L, Wentworth KL, Hsiao E. PMID: 34545360; PMCID: PMC8452110.
      View in: PubMed   Mentions:
    37. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021 08 05; 16(1):350. Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. PMID: 34353327; PMCID: PMC8340531.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    38. Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva. Calcif Tissue Int. 2021 12; 109(6):615-625. Warner SE, Kaplan FS, Pignolo RJ, Smith SE, Hsiao EC, De Cunto C, Di Rocco M, Harnett K, Grogan D, Genant HK. PMID: 34331548; PMCID: PMC8531122.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    39. ACVR1R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages. Bone. 2021 12; 153:116129. Matsuo K, Lepinski A, Chavez RD, Barruet E, Pereira A, Moody TA, Ton AN, Sharma A, Hellman J, Tomoda K, Nakamura MC, Hsiao EC. PMID: 34311122; PMCID: PMC8803261.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    40. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. Eur J Cancer. 2021 08; 153:8-15. Ch'ng S, Uyulmaz S, Carlino MS, Pennington TE, Shannon KF, Rtshiladze M, Stretch JR, Nieweg OE, Varey AHR, Hsiao E, Kapoor R, Pires da Silva I, Lo SN, Spillane AJ, Scolyer RA, Long GV, Hong AM, Saw RPM, Thompson JF, Menzies AM. PMID: 34126335.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva. Bone. 2021 09; 150:116016. Kaplan FS, Teachey DT, Andolina JR, Siegel DM, Mancilla EE, Hsiao EC, Al Mukaddam M, Rocke DM, Pignolo RJ. PMID: 34022457.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Global Wnt Inhibition With a Porcupine Inhibitor Decreases Established Trabecular Bone in a Mouse Model of Fibrous Dysplasia. Journal of the Endocrine Society. 2021 May 3; 5(Suppl 1):a234-a234. Lung LH, Moody MT, Wentworth WK, Kang KM, Ho HS, Hsiao HE. .
      View in: Publisher Site   Mentions:
    43. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021 02 27; 397(10276):797-804. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials . PMID: 33581798.
      View in: PubMed   Mentions: 282     Fields:    Translation:HumansCTClinical Trials
    44. Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva. Biomedicines. 2021 Feb 05; 9(2). Khan F, Yu X, Hsiao EC. PMID: 33562570; PMCID: PMC7915901.
      View in: PubMed   Mentions: 6  
    45. A Global Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. Osteologie/Osteology. 2021 Feb 1; 30(01):73-73. Mukaddam MM, Stockklausner SC, Pignolo PR, Baujat BG, Brown BM, De Cunto DC, Di Rocco DM, Hsiao HE, Keen KR, Le Quan Sang LK, Strahs SA, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    46. Use of Assistive Devices and Adaptations by Individuals with Fibrodysplasia Ossificans Progressiva (FOP): Data from a Global Natural History Study. Osteologie/Osteology. 2021 Feb 1; 30(01):75-75. Hsiao HE, Semler SJ, Mukaddam MM, Baujat BG, De Cunto DC, Keen KR, Pignolo PR, Harnett HK, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    47. Medications Used by Individuals with Fibrodysplasia Ossificans Progressiva (FOP): Data from a Global Natural History Study. Osteologie/Osteology. 2021 Feb 1; 30(01):73-74. Keen KR, Stockklausner SC, Mukaddam MM, Baujat BG, De Cunto DC, Hsiao HE, Pignolo PR, Harnett HK, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    48. Longitudinal and Flare-Up-Specific Biomarkers in Fibrodysplasia Ossificans Progressiva (FOP): Data from a Global Natural History Study. Osteologie/Osteology. 2021 Feb 1; 30(01):75-76. Pignolo PR, Semler SJ, Mukaddam MM, Baujat BG, De Cunto DC, Hsiao HE, Keen KR, Harnett HK, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    49. Virtual Interviews at Graduate Medical Education Training Programs: Determining Evidence-Based Best Practices. Acad Med. 2021 08 01; 96(8):1137-1145. Huppert LA, Hsiao EC, Cho KC, Marquez C, Chaudhry RI, Frank J, Goglin SE, Hsu G, Kathpalia P, Khanna R, Kompala T, Rao MN, Bower BA, Trafas V, Santhosh L, Schwartz BS, Babik JM. PMID: 33298691.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansPHPublic Health
    50. A natural history study of fibrodysplasia ossificans progressiva (FOP): 12-month outcome results. Bone Reports. 2020 Oct 1; 13:100607. Pignolo PR, Baujat BG, Brown BM, De Cunto DC, Di Rocco DM, Hsiao HE, Keen KR, Mukaddam MM, Le Quan Sang LK, Strahs SA, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    51. Measuring outcomes in ultra-rare bone diseases: Methodology of the palovarotene fibrodysplasia ossificans progressiva clinical development programme. Bone Reports. 2020 Oct 1; 13:100609. Pignolo PR, Baujat BG, Brown BM, De Cunto DC, Di Rocco DM, Hsiao HE, Keen KR, Mukaddam MM, Strahs SA, Grogan GD, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    52. A global natural history study of Fibrodysplasia Ossificans Progressiva (FOP): 12-month outcomes. Endocrine Abstracts. 2020 Aug 21. Mukaddam MM, Pignolo PR, Baujat BG, Brown BM, De DC, Di DR, Hsiao HE, Keen KR, Le LQ, Strahs SA, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    53. Patients with ACVR1R206H mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of Fibrodysplasia Ossificans Progressiva. Orphanet J Rare Dis. 2020 07 29; 15(1):193. Kou S, De Cunto C, Baujat G, Wentworth KL, Grogan DR, Brown MA, Di Rocco M, Keen R, Al Mukaddam M, le Quan Sang KH, Masharani U, Kaplan FS, Pignolo RJ, Hsiao EC. PMID: 32727600; PMCID: PMC7389682.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    54. MON-348 Surgical Management of Bilateral Hip Fracture in a Patient with Fibrodysplasia Ossificans Progressiva Treated with Palovarotene. Journal of the Endocrine Society. 2020 May 8; 4(Suppl 1). Singh SS, Kidane KJ, Wentworth WK, Motamedi MD, Morshed MS, Hsiao HE. .
      View in: Publisher Site   Mentions:
    55. OR29-05 A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. Journal of the Endocrine Society. 2020 May 8; 4(Suppl 1). Mukaddam MM, Pignolo PR, Baujat BG, Brown BM, De Cunto DC, Rocco RM, Hsiao HE, Keen KR, Sang SK, Strahs SA, Marino MR, Kaplan KF. .
      View in: Publisher Site   Mentions:
    56. MON-710 ACVR1 Activation in Primary and iPS-Derived Human Skeletal Muscle Stem Cells Impairs Myogenic Transcriptional Signature and Function. Journal of the Endocrine Society. 2020 May 8; 4(Supplement_1):mon-710-. Barruet BE, Garcia GS, Tamaki TS, Morales MB, Wu WJ, Moody MT, Pomerantz PJ, Hsiao HE. .
      View in: Publisher Site   Mentions:
    57. SUN-368 Wnt Inhibition Decreases Trabecular Bone in a Mouse Model of Fibrous Dysplasia. Journal of the Endocrine Society. 2020 May 8; 4(Suppl 1). Lung LH, Wentworth WK, Moody MT, Kang KM, Ho HS, Hsiao HE. .
      View in: Publisher Site   Mentions:
    58. SUN-344 Patients with Fibrodysplasia Ossificans Progressiva Have an Increased Prevalence of Cardiac Conduction Abnormalities. Journal of the Endocrine Society. 2020 May 8; 4(Suppl 1). Kou KS, DeCunto DC, Baujat BG, Wentworth WK, Grogan GD, Brown BM, Rocco RM, Keen KR, Mukaddam MM, Kaplan KF, Pignolo PR, Hsiao HE. .
      View in: Publisher Site   Mentions:
    59. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report. BMC Musculoskelet Disord. 2020 Apr 03; 21(1):204. Singh S, Kidane J, Wentworth KL, Motamedi D, Morshed S, Schober AE, Hsiao EC. PMID: 32245464; PMCID: PMC7126417.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    60. Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry. Bone. 2020 05; 134:115274. Pignolo RJ, Cheung K, Kile S, Fitzpatrick MA, De Cunto C, Al Mukaddam M, Hsiao EC, Baujat G, Delai P, Eekhoff EMW, Di Rocco M, Grunwald Z, Haga N, Keen R, Levi B, Morhart R, Scott C, Sherman A, Zhang K, Kaplan FS. PMID: 32062004.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    61. Advances in Models of Fibrous Dysplasia/McCune-Albright Syndrome. Front Endocrinol (Lausanne). 2019; 10:925. Lung H, Hsiao EC, Wentworth KL. PMID: 32038487; PMCID: PMC6993052.
      View in: PubMed   Mentions: 5     Fields:    
    62. Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification. Curr Osteoporos Rep. 2019 12; 17(6):387-394. Matsuo K, Chavez RD, Barruet E, Hsiao EC. PMID: 31721068; PMCID: PMC7271746.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    63. Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP). Bone Abstracts. 2019 Jul 31. Kaplan KF, Hsiao HE, Baujat BG, Keen KR, De DC, Di DR, Brown BM, Al AM, Grogan GD, Pignolo PR. .
      View in: Publisher Site   Mentions:
    64. Correction to: Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019 May 23; 14(1):113. Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, Keen R, Al Mukaddam M, Sang KLQ, Wilson A, White B, Grogan DR, Kaplan FS. PMID: 31122250; PMCID: PMC6532205.
      View in: PubMed   Mentions:    Fields:    
    65. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019 05 03; 14(1):98. Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, Keen R, Al Mukaddam M, Sang KLQ, Wilson A, White B, Grogan DR, Kaplan FS. PMID: 31053156; PMCID: PMC6499994.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    66. Effect of donor variation on osteogenesis and vasculogenesis in hydrogel cocultures. J Tissue Eng Regen Med. 2019 03; 13(3):433-445. Pennings I, van Dijk LA, van Huuksloot J, Fledderus JO, Schepers K, Braat AK, Hsiao EC, Barruet E, Morales BM, Verhaar MC, Rosenberg AJWP, Gawlitta D. PMID: 30650247; PMCID: PMC6593839.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    67. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2019 06; 85(6):1180-1187. Wentworth KL, Masharani U, Hsiao EC. PMID: 30501012; PMCID: PMC6533435.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    68. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight. 2018 11 15; 3(22). Barruet E, Morales BM, Cain CJ, Ton AN, Wentworth KL, Chan TV, Moody TA, Haks MC, Ottenhoff TH, Hellman J, Nakamura MC, Hsiao EC. PMID: 30429363; PMCID: PMC6302947.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    69. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019 06; 85(6):1199-1207. Hsiao EC, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Pignolo RJ, Grunwald Z, Netelenbos C, Keen R, Baujat G, Brown MA, Cho TJ, De Cunto C, Delai P, Haga N, Morhart R, Scott C, Zhang K, Diecidue RJ, Friedman CS, Kaplan FS, Eekhoff EMW. PMID: 30281842; PMCID: PMC6533500.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    70. Fibrodysplasia ossificans progressiva: a current review of imaging findings. Skeletal Radiol. 2018 Aug; 47(8):1043-1050. Bauer AH, Bonham J, Gutierrez L, Hsiao EC, Motamedi D. PMID: 29445932.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    71. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018 Jul - Aug; 8(4):230-238. Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A, Wheeler HR, Back M. PMID: 29730279.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    72. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva. Bone. 2018 04; 109:104-110. Wentworth KL, Bigay K, Chan TV, Ho JP, Morales BM, Connor J, Brooks E, Shahriar Salamat M, Sanchez HC, Wool G, Pignolo RJ, Kaplan FS, Hsiao EC. PMID: 29033382.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    73. The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva. Bone. 2018 04; 109:285-290. Mantick N, Bachman E, Baujat G, Brown M, Collins O, De Cunto C, Delai P, Eekhoff M, Zum Felde R, Grogan DR, Haga N, Hsiao E, Kantanie S, Kaplan F, Keen R, Milosevic J, Morhart R, Pignolo R, Qian X, di Rocco M, Scott C, Sherman A, Wallace M, Williams N, Zhang K, Bogard B. PMID: 28866367.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    74. Sirtuin-3 Promotes Adipogenesis, Osteoclastogenesis, and Bone Loss in Aging Male Mice. Endocrinology. 2017 09 01; 158(9):2741-2753. Ho L, Wang L, Roth TM, Pan Y, Verdin EM, Hsiao EC, Nissenson RA. PMID: 28911171; PMCID: PMC5659662.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    75. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. Bone. 2018 04; 109:276-280. Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, Whitehead B, Jacobs B, Siegel DM, Keen R, Hsiao E, Pignolo RJ. PMID: 28736245.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    76. Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva. Bone. 2018 04; 109:162-167. Barruet E, Hsiao EC. PMID: 28716551; PMCID: PMC5767535.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    77. Fibrodysplasia ossificans progressiva: baseline characteristics of 101 subjects participating in a global, longitudinal, natural history study. Bone Abstracts. 2017 Jul 11. Kaplan KF, Hsiao HE, Baujat BG, Brown BM, De DC, Di DR, Keen KR, Al AM, Grogan GD, Pignolo PR. .
      View in: Publisher Site   Mentions:
    78. International physician survey on management of FOP: a modified Delphi study. Orphanet J Rare Dis. 2017 06 12; 12(1):110. Di Rocco M, Baujat G, Bertamino M, Brown M, De Cunto CL, Delai PLR, Eekhoff EMW, Haga N, Hsiao E, Keen R, Morhart R, Pignolo RJ, Kaplan FS. PMID: 28606101; PMCID: PMC5468985.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    79. Fluorescent tagged episomals for stoichiometric induced pluripotent stem cell reprogramming. Stem Cell Res Ther. 2017 06 05; 8(1):132. Schmitt CE, Morales BM, Schmitz EMH, Hawkins JS, Lizama CO, Zape JP, Hsiao EC, Zovein AC. PMID: 28583172; PMCID: PMC5460403.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    80. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics. 2017; 7(5):1149-1158. Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL. PMID: 28435454; PMCID: PMC5399582.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    81. EPHRIN-B1 Mosaicism Drives Cell Segregation in Craniofrontonasal Syndrome hiPSC-Derived Neuroepithelial Cells. Stem Cell Reports. 2017 03 14; 8(3):529-537. Niethamer TK, Larson AR, O'Neill AK, Bershteyn M, Hsiao EC, Klein OD, Pomerantz JH, Bush JO. PMID: 28238796; PMCID: PMC5355632.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    82. The Rare Bone Disease Working Group: report from the 2016 American Society for Bone and Mineral Research Annual Meeting. Bone. 2017 Sep; 102:80-84. Drake MT, Collins MT, Hsiao EC. PMID: 28115283.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    83. BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13057-13062. Hayashi Y, Hsiao EC, Sami S, Lancero M, Schlieve CR, Nguyen T, Yano K, Nagahashi A, Ikeya M, Matsumoto Y, Nishimura K, Fukuda A, Hisatake K, Tomoda K, Asaka I, Toguchida J, Conklin BR, Yamanaka S. PMID: 27794120; PMCID: PMC5135304.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    84. Gs/Gi Regulation of Bone Cell Differentiation: Review and Insights from Engineered Receptors. Horm Metab Res. 2016 Nov; 48(11):689-699. Hsiao EC, Millard SM, Nissenson RA. PMID: 27643449.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    85. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Stem Cell Res Ther. 2016 08 17; 7(1):115. Barruet E, Morales BM, Lwin W, White MP, Theodoris CV, Kim H, Urrutia A, Wong SA, Srivastava D, Hsiao EC. PMID: 27530160; PMCID: PMC4988052.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    86. A Novel T55A Variant of Gs α Associated with Impaired cAMP Production, Bone Fragility, and Osteolysis. Case Rep Endocrinol. 2016; 2016:2691385. Wentworth K, Hsing A, Urrutia A, Zhu Y, Horvai AE, Bastepe M, Hsiao EC. PMID: 27579188; PMCID: PMC4992514.
      View in: PubMed   Mentions: 3  
    87. Loss of Iroquois homeobox transcription factors 3 and 5 in osteoblasts disrupts cranial mineralization. Bone Rep. 2016 Dec; 5:86-95. Cain CJ, Gaborit N, Lwin W, Barruet E, Ho S, Bonnard C, Hamamy H, Shboul M, Reversade B, Kayserili H, Bruneau BG, Hsiao EC. PMID: 27453922; PMCID: PMC4926823.
      View in: PubMed   Mentions: 14  
    88. Increased Gs Signaling in Osteoblasts Reduces Bone Marrow and Whole-Body Adiposity in Male Mice. Endocrinology. 2016 Apr; 157(4):1481-94. Cain CJ, Valencia JT, Ho S, Jordan K, Mattingly A, Morales BM, Hsiao EC. PMID: 26901092; PMCID: PMC4816728.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    89. Using Human Induced Pluripotent Stem Cells to Model Skeletal Diseases. Methods Mol Biol. 2016; 1353:101-18. Barruet E, Hsiao EC. PMID: 25549831.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    90. A Case of Hypercalcemia and Overexpression of CYP27B1 in Skeletal Muscle Lesions in a Patient with HIV Infection After Cosmetic Injections with Polymethylmethacrylate (PMMA) for Wasting. Calcif Tissue Int. 2015 Dec; 97(6):634-9. Hindi SM, Wang Y, Jones KD, Nussbaum JC, Chang Y, Masharani U, Bikle D, Shoback DM, Hsiao EC. PMID: 26253396; PMCID: PMC4861400.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    91. Maternal Hypercalcemia Due to Failure of 1,25-Dihydroxyvitamin-D3 Catabolism in a Patient With CYP24A1 Mutations. J Clin Endocrinol Metab. 2015 Aug; 100(8):2832-6. Shah AD, Hsiao EC, O'Donnell B, Salmeen K, Nussbaum R, Krebs M, Baumgartner-Parzer S, Kaufmann M, Jones G, Bikle DD, Wang Y, Mathew AS, Shoback D, Block-Kurbisch I. PMID: 26097993; PMCID: PMC4524985.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    92. Loss of Gi G-Protein-Coupled Receptor Signaling in Osteoblasts Accelerates Bone Fracture Healing. J Bone Miner Res. 2015 Oct; 30(10):1896-904. Wang L, Hsiao EC, Lieu S, Scott M, O'Carroll D, Urrutia A, Conklin BR, Colnot C, Nissenson RA. PMID: 25917236.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    93. Chronic recurrent multifocal osteomyelitis with an atypical presentation in an adult man. Skeletal Radiol. 2015 Sep; 44(9):1359-64. Hong CW, Hsiao EC, Horvai AE, Link TM. PMID: 25771734.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    94. Assessing the osteoblast transcriptome in a model of enhanced bone formation due to constitutive Gs-G protein signaling in osteoblasts. Exp Cell Res. 2015 May 01; 333(2):289-302. Wattanachanya L, Wang L, Millard SM, Lu WD, O'Carroll D, Hsiao EC, Conklin BR, Nissenson RA. PMID: 25704759; PMCID: PMC4408231.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    95. Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci. 2015 Mar; 18(3):423-34. Orr AG, Hsiao EC, Wang MM, Ho K, Kim DH, Wang X, Guo W, Kang J, Yu GQ, Adame A, Devidze N, Dubal DB, Masliah E, Conklin BR, Mucke L. PMID: 25622143; PMCID: PMC4340760.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansAnimalsCells
    96. Disrupted bone remodeling leads to cochlear overgrowth and hearing loss in a mouse model of fibrous dysplasia. PLoS One. 2014; 9(5):e94989. Akil O, Hall-Glenn F, Chang J, Li A, Chang W, Lustig LR, Alliston T, Hsiao EC. PMID: 24788917; PMCID: PMC4006800.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    97. Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK. J Bone Miner Res. 2014 Apr; 29(4):911-21. Schafer AL, Mumm S, El-Sayed I, McAlister WH, Horvai AE, Tom AM, Hsiao EC, Schaefer FV, Collins MT, Anderson MS, Whyte MP, Shoback DM. PMID: 24014458; PMCID: PMC4419358.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    98. Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells. Nature. 2014 Mar 06; 507(7490):99-103. Bershteyn M, Hayashi Y, Desachy G, Hsiao EC, Sami S, Tsang KM, Weiss LA, Kriegstein AR, Yamanaka S, Wynshaw-Boris A. PMID: 24413397; PMCID: PMC4030630.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    99. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis. 2013 Dec 09; 8:190. Matsumoto Y, Hayashi Y, Schlieve CR, Ikeya M, Kim H, Nguyen TD, Sami S, Baba S, Barruet E, Nasu A, Asaka I, Otsuka T, Yamanaka S, Conklin BR, Toguchida J, Hsiao EC. PMID: 24321451; PMCID: PMC3892046.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    100. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013 Sep 05; 13(3):285-99. Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegué E. PMID: 23850243; PMCID: PMC3769504.
      View in: PubMed   Mentions: 341     Fields:    Translation:HumansAnimalsCells
    101. AKAP13 Rho-GEF and PKD-binding domain deficient mice develop normally but have an abnormal response to β-adrenergic-induced cardiac hypertrophy. PLoS One. 2013; 8(4):e62705. Spindler MJ, Burmeister BT, Huang Y, Hsiao EC, Salomonis N, Scott MJ, Srivastava D, Carnegie GK, Conklin BR. PMID: 23658642; PMCID: PMC3637253.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    102. Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. Blood. 2012 Oct 25; 120(17):3425-35. Schepers K, Hsiao EC, Garg T, Scott MJ, Passegué E. PMID: 22859604; PMCID: PMC3482855.
      View in: PubMed   Mentions: 43     Fields:    Translation:AnimalsCells
    103. Mineral composition is altered by osteoblast expression of an engineered G(s)-coupled receptor. Calcif Tissue Int. 2011 Jul; 89(1):10-20. Kazakia GJ, Speer D, Shanbhag S, Majumdar S, Conklin BR, Nissenson RA, Hsiao EC. PMID: 21526395; PMCID: PMC3110278.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    104. Constitutive Gs activation using a single-construct tetracycline-inducible expression system in embryonic stem cells and mice. Stem Cell Res Ther. 2011 Mar 04; 2(2):11. Hsiao EC, Nguyen TD, Ng JK, Scott MJ, Chang WC, Zahed H, Conklin BR. PMID: 21375737; PMCID: PMC3226282.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    105. Reporter-based isolation of induced pluripotent stem cell- and embryonic stem cell-derived cardiac progenitors reveals limited gene expression variance. Circ Res. 2010 Aug 06; 107(3):340-7. van Laake LW, Qian L, Cheng P, Huang Y, Hsiao EC, Conklin BR, Srivastava D. PMID: 20558827; PMCID: PMC2919280.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    106. Gs G protein-coupled receptor signaling in osteoblasts elicits age-dependent effects on bone formation. J Bone Miner Res. 2010 Mar; 25(3):584-93. Hsiao EC, Boudignon BM, Halloran BP, Nissenson RA, Conklin BR. PMID: 20200944; PMCID: PMC3153396.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    107. Ligand-mediated activation of an engineered gs g protein-coupled receptor in osteoblasts increases trabecular bone formation. Mol Endocrinol. 2010 Mar; 24(3):621-31. Hsiao EC, Millard SM, Louie A, Huang Y, Conklin BR, Nissenson RA. PMID: 20150184; PMCID: PMC2840804.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    108. Engineering GPCR signaling pathways with RASSLs. Nat Methods. 2008 Aug; 5(8):673-8. Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, Forsayeth JR, Guettier JM, Chang WC, Pei Y, McCarthy KD, Nissenson RA, Wess J, Bockaert J, Roth BL. PMID: 18668035; PMCID: PMC2703467.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansAnimalsCells
    109. Marking embryonic stem cells with a 2A self-cleaving peptide: a NKX2-5 emerald GFP BAC reporter. PLoS One. 2008 Jul 02; 3(7):e2532. Hsiao EC, Yoshinaga Y, Nguyen TD, Musone SL, Kim JE, Swinton P, Espineda I, Manalac C, deJong PJ, Conklin BR. PMID: 18596956; PMCID: PMC2430532.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    110. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell. 2008 Mar 06; 2(3):219-29. Ivey KN, Muth A, Arnold J, King FW, Yeh RF, Fish JE, Hsiao EC, Schwartz RJ, Conklin BR, Bernstein HS, Srivastava D. PMID: 18371447; PMCID: PMC2293325.
      View in: PubMed   Mentions: 274     Fields:    Translation:HumansAnimalsCells
    111. Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1209-14. Hsiao EC, Boudignon BM, Chang WC, Bencsik M, Peng J, Nguyen TD, Manalac C, Halloran BP, Conklin BR, Nissenson RA. PMID: 18212126; PMCID: PMC2234117.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    112. Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLoS One. 2007 Dec 19; 2(12):e1317. Chang WC, Ng JK, Nguyen T, Pellissier L, Claeysen S, Hsiao EC, Conklin BR. PMID: 18338032; PMCID: PMC2267039.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    113. Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. Proc Natl Acad Sci U S A. 2007 Jun 26; 104(26):10894-9. Kwon C, Arnold J, Hsiao EC, Taketo MM, Conklin BR, Srivastava D. PMID: 17576928; PMCID: PMC1904134.
      View in: PubMed   Mentions: 126     Fields:    Translation:AnimalsCells
    114. A Series of RASSLs Activated by a Single Agonist. The FASEB Journal. 2006 Mar 1; 20(4):a249-a249. Chang CP, Hsiao HE, Zambon ZA, Conklin CB. .
      View in: Publisher Site   Mentions:
    115. Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res. 2006 Jan; 130(1):45-51. Zimmers TA, Jin X, Hsiao EC, Perez EA, Pierce RH, Chavin KD, Koniaris LG. PMID: 16154591.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    116. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock. 2005 Jun; 23(6):543-8. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG. PMID: 15897808.
      View in: PubMed   Mentions: 93     Fields:    Translation:AnimalsCells
    117. An unusual development. Am J Med. 2005 Jun; 118(6):609-11. Hsiao E, Charles R, Magid C, Nivatpumin P, Wiener CM. PMID: 15922691.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab. 2005 Jul; 90(7):4350-6. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW. PMID: 15870121.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    119. Diagnostic I-123 scintigraphy to assess potential breast uptake of I-131 before radioiodine therapy in a postpartum woman with thyroid cancer. Clin Nucl Med. 2004 Aug; 29(8):498-501. Hsiao E, Huynh T, Mansberg R, Bautovich G, Roach P. PMID: 15249829.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    120. Cases from the Osler medical service at Johns Hopkins University. Am J Med. 2004 Apr 01; 116(7):490-2. Maruthur NM, Hsiao EC, Lee J, Nivatpumin P. PMID: 15047040.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    121. Transient absence of hepatic uptake on gallium-67 scintigraphy following fludarabine therapy. Clin Nucl Med. 2004 Apr; 29(4):275-6. Huynh T, Mansberg R, Hsiao E, Coyle L, Roach P. PMID: 15096981.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    122. Pericarditis associated with cryptococcal meningitis on Ga-67 scintigraphy. Clin Nucl Med. 2004 Feb; 29(2):119-20. Hsiao E, Mansberg R, Huynh T, Roach P. PMID: 14734914.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    123. Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration. J Immunol. 2001 Jul 01; 167(1):399-406. Koniaris LG, Zimmers-Koniaris T, Hsiao EC, Chavin K, Sitzmann JV, Farber JM. PMID: 11418676.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    124. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol. 2000 May; 20(10):3742-51. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. PMID: 10779363; PMCID: PMC85678.
      View in: PubMed   Mentions: 121     Fields:    Translation:AnimalsCells
    125. Structural and functional conservation of the Drosophila doublesex splicing enhancer repeat elements. RNA. 1996 Oct; 2(10):969-81. Hertel KJ, Lynch KW, Hsiao EC, Liu EH, Maniatis T. PMID: 8849774; PMCID: PMC1369430.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells